DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025
DiaMedica Therapeutics (Nasdaq: DMAC) announced it will release its full-year 2024 financial results after market close on March 17th, 2025, followed by a conference call on March 18th at 7:00 AM Central Time. The company will provide a business update during the call.
DiaMedica is a clinical-stage biopharmaceutical company developing treatments for severe ischemic diseases. Their lead candidate DM199 is the first pharmaceutically active recombinant form of the KLK1 protein, targeting acute ischemic stroke and preeclampsia. The protein has established therapeutic applications in Asia for treating various vascular diseases.
DiaMedica Therapeutics (Nasdaq: DMAC) ha annunciato che rilascerà i risultati finanziari dell'intero anno 2024 dopo la chiusura del mercato il 17 marzo 2025, seguito da una conferenza telefonica il 18 marzo alle 7:00 ora centrale. L'azienda fornirà un aggiornamento aziendale durante la chiamata.
DiaMedica è un'azienda biofarmaceutica in fase clinica che sviluppa trattamenti per malattie ischemiche gravi. Il loro candidato principale DM199 è la prima forma ricombinante attiva farmacologicamente della proteina KLK1, mirata all'ictus ischemico acuto e alla preeclampsia. La proteina ha applicazioni terapeutiche consolidate in Asia per il trattamento di varie malattie vascolari.
DiaMedica Therapeutics (Nasdaq: DMAC) anunció que publicará sus resultados financieros del año completo 2024 después del cierre del mercado el 17 de marzo de 2025, seguido de una conferencia telefónica el 18 de marzo a las 7:00 AM, hora central. La compañía proporcionará una actualización empresarial durante la llamada.
DiaMedica es una empresa biofarmacéutica en etapa clínica que desarrolla tratamientos para enfermedades isquémicas severas. Su candidato principal DM199 es la primera forma recombinante activa farmacológicamente de la proteína KLK1, dirigida al accidente cerebrovascular isquémico agudo y a la preeclampsia. La proteína tiene aplicaciones terapéuticas establecidas en Asia para el tratamiento de diversas enfermedades vasculares.
DiaMedica Therapeutics (Nasdaq: DMAC)는 2025년 3월 17일 시장 마감 후 2024년 전체 연도 재무 결과를 발표할 것이라고 발표했으며, 3월 18일 오전 7시 중앙 시간에 컨퍼런스 콜이 이어질 것입니다. 회사는 통화 중에 사업 업데이트를 제공할 예정입니다.
DiaMedica는 중증 허혈성 질환 치료제를 개발하는 임상 단계의 생명공학 회사입니다. 그들의 주요 후보 DM199는 KLK1 단백질의 첫 번째 약리학적으로 활성화된 재조합 형태로, 급성 허혈성 뇌졸중 및 자간전증을 목표로 하고 있습니다. 이 단백질은 아시아에서 다양한 혈관 질환 치료에 대한 치료 응용이 확립되어 있습니다.
DiaMedica Therapeutics (Nasdaq: DMAC) a annoncé qu'elle publiera ses résultats financiers pour l'année complète 2024 après la fermeture du marché le 17 mars 2025, suivie d'une conférence téléphonique le 18 mars à 7h00, heure centrale. L'entreprise fournira une mise à jour sur ses activités lors de l'appel.
DiaMedica est une entreprise biopharmaceutique en phase clinique développant des traitements pour des maladies ischémiques sévères. Leur candidat principal DM199 est la première forme recombinante active sur le plan pharmacologique de la protéine KLK1, ciblant l'accident vasculaire cérébral ischémique aigu et la prééclampsie. La protéine a des applications thérapeutiques établies en Asie pour le traitement de diverses maladies vasculaires.
DiaMedica Therapeutics (Nasdaq: DMAC) gab bekannt, dass es seine Finanzzahlen für das gesamte Jahr 2024 nach Börsenschluss am 17. März 2025 veröffentlichen wird, gefolgt von einer Telefonkonferenz am 18. März um 7:00 Uhr Central Time. Das Unternehmen wird während des Anrufs ein Update zur Geschäftslage geben.
DiaMedica ist ein biopharmazeutisches Unternehmen in der klinischen Phase, das Behandlungen für schwere ischämische Erkrankungen entwickelt. Ihr Hauptkandidat DM199 ist die erste pharmazeutisch aktive rekombinante Form des KLK1-Proteins, das auf akuten ischämischen Schlaganfall und Präeklampsie abzielt. Das Protein hat in Asien etablierte therapeutische Anwendungen zur Behandlung verschiedener Gefäßerkrankungen.
- None.
- None.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that its full-year 2024 financial results will be released after the markets close on Monday, March 17th. DiaMedica will host a live conference call on Tuesday, March 18th at 7:00 AM Central Time to provide a business update and discuss financial results.
Conference Call details:
Date: |
Tuesday, March 18, 2025 |
Time: |
7:00 AM CDT / 8:00 AM EDT |
Web access: |
|
Dial In: |
(800) 836-8184 |
Conference ID: |
50034 |
Interested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for play back on the Company’s website, under investor relations - events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until March 25, 2025, by dialing (888) 660-6345 (US Toll Free) and entering the replay passcode: 50034#.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on acute ischemic stroke and preeclampsia. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250311371863/en/
Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
skellen@diamedica.com
For Investor Inquiries:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
Source: DiaMedica Therapeutics Inc.
FAQ
When will DiaMedica Therapeutics (DMAC) release its 2024 financial results?
What is DiaMedica's (DMAC) lead drug candidate and its target conditions?
When is DiaMedica's (DMAC) Q4 2024 earnings conference call scheduled?
How long will DiaMedica's (DMAC) Q4 2024 earnings call webcast be available for replay?
